Extended-release tofacitinib for refractory Behçet disease
Abstract. Rationale:. Although single-cytokine inhibitors can be considered in treating severe or refractory Behçet disease (BD), these biologic agents are associated with potential therapeutic failure due to the multi-cytokine pathogenesis involving Th1- and Th17-type cytokines with activated Janus...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2022-04-01
|
| Series: | Medicine |
| Online Access: | http://journals.lww.com/10.1097/MD.0000000000029189 |